Nathan R. Foster
YOU?
Author Swipe
View article: Supplementary Table S6 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Table S6 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
Background Information on Advanced Adenoma
View article: Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
MUC1 expression and immune infiltrate in baseline and recurrent adenoma pairs
View article: Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
Endpoint titers of plasma antibodies at week 12 amongst vaccine responders
View article: Supplementary Methods S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Methods S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
supplementary methods: trial administration
View article: Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
Baseline advanced adenoma characteristics
View article: Designing allosteric modulators to change GPCR G protein subtype selectivity
Designing allosteric modulators to change GPCR G protein subtype selectivity Open
G-protein-coupled receptors (GPCRs) convert extracellular signals into intracellular responses by signalling through 16 subtypes of Gα proteins and two β-arrestin proteins. Biased compounds-molecules that preferentially activate a subset o…
View article: Epidemiologic Method Review at Scale: Assessing Charlson Comorbidity Versioning Using a Large Language Model
Epidemiologic Method Review at Scale: Assessing Charlson Comorbidity Versioning Using a Large Language Model Open
The Charlson Comorbidity Index (CCI) is widely used in epidemiologic studies. However, many versions of the CCI have been developed since the original method was published in 1987, and it is unclear which version is used most frequently an…
View article: A Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
A Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer Open
Background Smoking is the most common etiology for lung cancer and smoking cessation does not eliminate the risk. Mucin (MUC)1 glycoprotein is aberrantly expressed in lung carcinomas and premalignant lung lesions. We explored whether a MUC…
View article: Design of allosteric modulators that change GPCR G protein subtype selectivity
Design of allosteric modulators that change GPCR G protein subtype selectivity Open
G protein-coupled receptors (GPCRs), the largest family of drug targets, can signal through 16 subtypes of Gα proteins. Biased compounds that selectively activate therapy-relevant pathways promise to be safer, more effective medications. T…
View article: Design of allosteric modulators that change GPCR G protein subtype selectivity
Design of allosteric modulators that change GPCR G protein subtype selectivity Open
G protein-coupled receptors (GPCRs), the largest family of drug targets, can signal through 16 subtypes of Gα proteins. Biased compounds that selectively activate therapy-relevant pathways promise to be safer, more effective medications. T…
View article: The Global Prevalence of Iron Deficiency in Collegiate Athletes: A Systematic Review and Meta‐Analysis
The Global Prevalence of Iron Deficiency in Collegiate Athletes: A Systematic Review and Meta‐Analysis Open
Athletes are at high risk of iron deficiency even without anemia. In this systematic review and meta‐analysis that included 17,519 athletes in 122 references from 23 countries, participating in 62 unique sports over a 41‐year timeframe, ap…
View article: Iron Deficiency in Collegiate Athletes Obtaining Preparticipation Hemoglobinopathy Screening in the Upper Midwest
Iron Deficiency in Collegiate Athletes Obtaining Preparticipation Hemoglobinopathy Screening in the Upper Midwest Open
Objective Iron and other biologically important metals are essential to mitochondrial function but are not routinely evaluated. Their equilibrium is critical to the optimal performance of cells with high metabolic activity such as neurons,…
View article: Prognostic Factors in Limited-Stage Small Cell Lung Cancer
Prognostic Factors in Limited-Stage Small Cell Lung Cancer Open
Importance The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors from the Cancer and Leukemia Gr…
View article: Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Flow cytometry gating strategy in PBMC
View article: Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Supplementary Table 1. Representativeness of Study Participants Supplementary Table 2. Adverse Events (regardless of attribution) Supplementary Table 3. Archival Tumor Biomarker Analyses in Cohort 1 Supplementary Table 4. Archival Tumor Bi…
View article: Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Myeloid subset frequency in peripheral blood before and on treatment
View article: Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Myeloid subset frequency in peripheral blood before and on treatment
View article: Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Increased HED and HLA diversity are not associated with improved PFS
View article: Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
NLR and MLR before and on treatment
View article: Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Purpose:Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting fur…
View article: Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
NLR and MLR before and on treatment
View article: Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Tumor density of CD8 T cells and myeloid subsets in DTC tumors
View article: Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Peripheral T cell subsets and response
View article: Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Supplementary Table 1. Representativeness of Study Participants Supplementary Table 2. Adverse Events (regardless of attribution) Supplementary Table 3. Archival Tumor Biomarker Analyses in Cohort 1 Supplementary Table 4. Archival Tumor Bi…
View article: Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Increased HED and HLA diversity are not associated with improved PFS
View article: Supplementary Figure S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Consort diagram
View article: Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Tumor density of CD8 T cells and myeloid subsets in DTC tumors
View article: Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Peripheral T cell subsets and response
View article: Supplementary Figure S2 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S2 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
T cell and myeloid cell staining in DTC tumors
View article: Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Flow cytometry gating strategy in PBMC